Other genes involved in EGFR downstream pathways, such as BRAF, PIK3CA and PTEN, might be involved in the development of resistance mechanisms to cetuximab and panitumumab in CRC, although their role is not completely clarified [10–12]. Here, EGFR is linked to colorectal carcinoma.